BiotechTube

Aranesp®

ApprovedCompleted
0 watching 0 views this week🔥 Hot
84
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Anemia

Conditions

Anemia

Trial Timeline

— → —

NCT ID
NCT00117065

About Aranesp®

Aranesp® is a approved stage product being developed by Amgen for Anemia. The current trial status is completed. This product is registered under clinical trial identifier NCT00117065. Target conditions include Anemia.

Hype Score Breakdown

Clinical
30
Activity
20
Company
9
Novelty
10
Community
12

Clinical Trials (8)

NCT IDPhaseStatus
NCT00117078ApprovedCompleted
NCT00117104ApprovedCompleted
NCT00117065ApprovedCompleted
NCT00117130ApprovedCompleted
NCT00144131Phase 2Completed
NCT00116701Phase 3Completed
NCT00117039ApprovedCompleted
NCT00111995ApprovedCompleted

Competing Products

20 competing products in Anemia

See all competitors
ProductCompanyStageHype Score
KER-047Keros TherapeuticsPhase 2
44
LY2787106Eli LillyPhase 1
33
R744 + R744Chugai PharmaceuticalPhase 3
77
epoetin beta + placeboChugai PharmaceuticalPhase 3
77
recombinant human erythropoietin + recombinant human erythropoietin placeboChugai PharmaceuticalPhase 3
77
recombinant human erythropoietin + recombinant human erythropoietinChugai PharmaceuticalPhase 3
77
darbepoetin alfaAmgenPhase 3
76
PrasugrelDaiichi SankyoPhase 1
33
Prasugrel + PlaceboDaiichi SankyoPhase 2
52
roxadustatAstellas PharmaPhase 3
77
roxadustatAstellas PharmaPhase 3
77
Roxadustat + Darbepoetin alfaAstellas PharmaPhase 3
77
AlefaceptAstellas PharmaPhase 1
33
RoxadustatAstellas PharmaPhase 2
52
roxadustatAstellas PharmaPhase 1
33
Roxadustat + PlaceboAstellas PharmaPhase 3
77
RoxadustatAstellas PharmaPre-clinical
23
Roxadustat + Epoetin AlfaAstellas PharmaPhase 3
77
roxadustat + Darbepoetin alfaAstellas PharmaPhase 3
77
roxadustatAstellas PharmaPhase 3
77

Other Products from Amgen

PanitumumabApproved
84
EvolocumabApproved
84
Prolia®Approved
84
EvolocumabApproved
84
DenosumabApproved
84